Our results highlight the potential of high-dose ω-3PUFA supplementation as a mediator of increased insulin sensitivity in subjects with obesity, insulin resistance and elevated biomarkers of plasma and AT inflammation. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.